2018 American Transplant Congress
Precision Medicine for Determining the Efficacy of a Novel Belatacept Regimen
Transplant Nephrology, UCSF, San Francisco, CA.
IntroBelatacept is increasingly used as maintenance immunosuppression to improve long term outcomes in kidney transplant. Since acute rejection in patients on belatacept have been noted…2018 American Transplant Congress
Cognition after Belatacept Conversion
Yale University, New Haven, CT.
Intro: Kidney Transplant Recipients (KTRs) taking calcineurin inhibitors (CNIs) can experience varying drug toxicities. Less well studied compared to the metabolic consequences, many patients report…2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…2018 American Transplant Congress
Urinary CXCL9 Monitoring to Accompany a Safe CNI-to-Belatacept Conversion in Kidney Transplant Patients
Background: Converting renal transplant recipients from CNI to belatacept immunosuppression has been proposed as a strategy to limit nephrotoxicity, but it is associated with an…2017 American Transplant Congress
Increased Ischemic Inflammation Induces Recipient Endogenous Memory CD4 Cell-Graft Dendritic Cell Interactions to Provide Help for Activation of Endogenous Memory CD8 T Cells.
Immunology, Cleveland Clinic, Cleveland, OH
Memory T cells provide protection against recurrent pathogens, but memory T cells with donor-reactivity pose a major barrier to successful allograft transplant and tolerance induction.…2017 American Transplant Congress
Evaluation of Function and TCR signaling Profile of CD57+ T Cells in Allo-Specific Immunity.
Our studies have showed that CD57+ cells are resistant to B7 costimulation blockade (CoB). We hypothesize that CD57+ cells are highly sensitive to T cell…2017 American Transplant Congress
Rapid Depletion of Circulating DSA and Treatment of Acute Antibody-Mediated Rejection with the Combination of CTLA-4Ig/Belatacept and Bortezomib in Mouse and Man.
1Sugery, University of Chicago, Chicago, IL; 2Surgery, The Ohio State University, Columbus, OH
Antibody mediated rejection (AMR) is a major cause of rejection, and there are limited therapeutic options for reversing alloantibody production when it is fully established.…2017 American Transplant Congress
Kidney Recipients with 10 Year Belatacept-Treatment Display an Altered T Cell Subset Composition and Low Plasma Cytokine Levels Compared to Matched Patients with CNI-Based Immunosuppression.
Introduction/BackgroundMore than 10 years ago, Belatacept (Bela)-based immunosuppression was investigated in the BENEFIT trial of kidney transplantation (KTx) compared to CNI-based immunosuppression. Bela inhibits T…2017 American Transplant Congress
TIM-4 Identifies Pro-Inflammatory B Effector Cells That Are Potent Drivers of Alloimmunity and Allograft Rejection Through Expression of Both IFN-γ and IL-17.
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh
B cells can either augment or inhibit immune responses due to the presence both regulatory (Bregs) and effector (Beff) B cells expressing anti- or pro-…2017 American Transplant Congress
The Treg/Th17 Axis: A Dynamic Balance Regulated by Stromal Laminins.
University of Maryland, Baltimore
Background: Our recent work demonstrated that laminins α4β1γ1 and α5β1γ1, components of the lymph node (LN) stroma, are differentially regulated. Tolerance is associated with relatively…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 30
- Next Page »